author-photo

Christina Balser

Praxis

19

Papers

1513

Citations

Citation Trend

Filter By

Papers (13) Sort By

Journal Conference Others

IBRUTINIB VERSUS PLACEBO IN PATIENTS WITH ASYMPTOMATIC, TREATMENT‐NAÏVE EARLY STAGE CLL: PRIMARY ENDPOINT RESULTS OF THE PHASE 3 DOUBLE‐BLIND RANDOMIZED CLL12 TRIAL

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (24)
Four versus Two Years of Rituximab Maintenance (R-Maintenance) Following Bendamustine Plus Rituximab (B-R): Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN Study)

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (3)
Four Versus Two Years of Rituximab Maintenance (R-maintenance) Following Bendamustine Plus Rituximab (B-R): Initial Results of a Prospective, Randomized Multicenter Phase 3 Study in First-Line Follicular Lymphoma (the StiL NHL7-2008 MAINTAIN study)

2017 Blood
Show All
- Source
- Cite
- Save
Citations (10)
Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas: Nine-year updated results from the StiL NHL1 study.

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (42)
Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial

2016 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (92)
Ibrutinib in Early Stage CLL: Preliminary Safety Results of a Placebo-Controlled Phase III Study

2015 Blood
Show All
- Source
- Cite
- Save
Citations (5)
Bendamustine Plus Rituximab Followed By Rituximab Maintenance for Patients with Untreated Advanced Follicular Lymphomas. Results from the StiL NHL 7-2008 Trial (MAINTAIN trial) (ClinicalTrials.gov Identifier: NCT00877214)

2014 Blood
Show All
- Source
- Cite
- Save
Citations (5)
Subanalysis of the StiL NHL 1–2003 Study: Achievement of Complete Response with Bendamustine-Rituximab (B-R) and CHOP-R in the First-Line Treatment of Indolent and Mantle Cell Lymphomas Results in Superior Survival Compared to Partial Response.

2012 Blood
Show All
- Source
- Cite
- Save
Citations (2)
A novel type of congenital hypochromic anemia associated with a nonsense mutation in the STEAP3/TSAP6 gene.

2011 Blood
Show All
- Source
- Cite
- Save
Citations (36)
Genetic anemia in three siblings associated with a nonsense codon of STEAP3 and low expression of the normal allele

2010 Transfusion Clinique Et Biologique
Show All
- Source
- Cite
- Save
Citations (0)